1085 related articles for article (PubMed ID: 32815454)
1. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
2. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
3. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
4. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
5. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
7. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
Thethi TK; Pratley R; Meier JJ
Diabetes Obes Metab; 2020 Aug; 22(8):1263-1277. PubMed ID: 32267058
[TBL] [Abstract][Full Text] [Related]
9. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR; Blonde L; Pratley RE
Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
[TBL] [Abstract][Full Text] [Related]
10. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ
Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
[TBL] [Abstract][Full Text] [Related]
14. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Ard J; Fitch A; Fruh S; Herman L
Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
[TBL] [Abstract][Full Text] [Related]
15. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
[TBL] [Abstract][Full Text] [Related]
16. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
17. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Campos C; Unger J
Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
[TBL] [Abstract][Full Text] [Related]
18. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Xie Z; Hu J; Gu H; Li M; Chen J
Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
[TBL] [Abstract][Full Text] [Related]
20. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
Kim HS; Jung CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
